Loading
VasGene Therapeutics
VasGene is a Los Angeles biotech developing a soluble EphB4 decoy protein that starves tumours of blood supply and reawakens immune cells, tested with checkpoint inhibitors in bladder and head and neck cancer.
Also called: Vasgene Therapeutics, IncVasGene
Overview
VasGene Therapeutics, based in Los Angeles and spun out of the University of Southern California, develops sEphB4-HSA, a soluble EphB4 receptor fused to albumin that blocks ephrin-B2 signalling on tumour vessels and immune cells. It has been tested with pembrolizumab in urothelial cancer and in head and neck cancer, and is registered on ClinicalTrials.gov under VasGene as lead sponsor of a phase 3 trial.
Connected
5Similar pages
- CompanyMonopar Therapeutics
Shares Pivotal (registrational) trial, Clinical trial, Head and neck squamous cell carcinoma.
- CompanyPregLem
- CompanyAgennix
- CompanyLisata Therapeutics
- CompanyImmunitor
- CompanyEmergent BioSolutions
- CompanyHarbour BioMed
- CompanyVion Pharmaceuticals
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
ClinicalTrials.gov · 1
vasgene.com · 1
wikidata.org · 1
A source that has moved or gone is reported by the weekly link check. /audit/